中华肾脏病杂志
中華腎髒病雜誌
중화신장병잡지
2014年
4期
262-266
,共5页
钟美容%彭晖%赵文波%王成%张俊%刘迅%李远清%Sujay Dutta Paude%王倩倩
鐘美容%彭暉%趙文波%王成%張俊%劉迅%李遠清%Sujay Dutta Paude%王倩倩
종미용%팽휘%조문파%왕성%장준%류신%리원청%Sujay Dutta Paude%왕천천
微RNAs%糖尿病肾病%生物学标记%microRNA-29
微RNAs%糖尿病腎病%生物學標記%microRNA-29
미RNAs%당뇨병신병%생물학표기%microRNA-29
MicroRNAs%Diabetic nephropathies%Biological markers%MicroRNA-29
目的 探讨2型糖尿病患者尿上清的microRNA-29 (miR-29)水平作为糖尿病肾病的生物标志物的可能性.方法 收集61例2型糖尿病患者的清晨首次中段尿,根据尿白蛋白水平分为糖尿病无蛋白尿组[n=25,(58.88±11.75)岁]和糖尿病有蛋白尿组[n=36,(62.19±13.11)岁].用实时荧光定量PCR法检测尿上清miR-29a、miR-29b和miR-29c的水平.等量的外源性人工合成的cel-miR-39加入等体积的尿上清中用于校正miR-29的水平.同时收集尿白蛋白排泄率、血肌酐、尿素氮、糖化血红蛋白(HbAlc)、血脂等其他生化指标.而眼底检查的结果则作为评估糖尿病小血管病变的指标.结果 2型糖尿病有、无蛋白尿两组之间HbAlc水平及糖尿病病程差异无统计学意义,而2型糖尿病有蛋白尿组估算肾小球滤过率(eGRF)水平显著低于无蛋白尿组(P=0.001),2型糖尿病有蛋白尿组尿上清miR-29a、miR-29b和miR-29c 水平高于无蛋白尿组(P=0.029、0.032、0.040).2型糖尿病尿白蛋白排泄率与尿上清miR-29a 及miR-29b水平相关(r=0.284,P=0.039;r=0.275,P=0.046),尿上清miR-29b水平与尿素氮水平相关(r=0.277,P=0.031),而miR-29水平与上述其他各项临床指标无相关.结论 2型糖尿病患者尿上清miR-29a及miR-29b水平与尿白蛋白水平相关.尿上清miR-29作为2型糖尿病患者糖尿病肾病的生物标志物的潜能有待进一步的探索和评估.
目的 探討2型糖尿病患者尿上清的microRNA-29 (miR-29)水平作為糖尿病腎病的生物標誌物的可能性.方法 收集61例2型糖尿病患者的清晨首次中段尿,根據尿白蛋白水平分為糖尿病無蛋白尿組[n=25,(58.88±11.75)歲]和糖尿病有蛋白尿組[n=36,(62.19±13.11)歲].用實時熒光定量PCR法檢測尿上清miR-29a、miR-29b和miR-29c的水平.等量的外源性人工閤成的cel-miR-39加入等體積的尿上清中用于校正miR-29的水平.同時收集尿白蛋白排洩率、血肌酐、尿素氮、糖化血紅蛋白(HbAlc)、血脂等其他生化指標.而眼底檢查的結果則作為評估糖尿病小血管病變的指標.結果 2型糖尿病有、無蛋白尿兩組之間HbAlc水平及糖尿病病程差異無統計學意義,而2型糖尿病有蛋白尿組估算腎小毬濾過率(eGRF)水平顯著低于無蛋白尿組(P=0.001),2型糖尿病有蛋白尿組尿上清miR-29a、miR-29b和miR-29c 水平高于無蛋白尿組(P=0.029、0.032、0.040).2型糖尿病尿白蛋白排洩率與尿上清miR-29a 及miR-29b水平相關(r=0.284,P=0.039;r=0.275,P=0.046),尿上清miR-29b水平與尿素氮水平相關(r=0.277,P=0.031),而miR-29水平與上述其他各項臨床指標無相關.結論 2型糖尿病患者尿上清miR-29a及miR-29b水平與尿白蛋白水平相關.尿上清miR-29作為2型糖尿病患者糖尿病腎病的生物標誌物的潛能有待進一步的探索和評估.
목적 탐토2형당뇨병환자뇨상청적microRNA-29 (miR-29)수평작위당뇨병신병적생물표지물적가능성.방법 수집61례2형당뇨병환자적청신수차중단뇨,근거뇨백단백수평분위당뇨병무단백뇨조[n=25,(58.88±11.75)세]화당뇨병유단백뇨조[n=36,(62.19±13.11)세].용실시형광정량PCR법검측뇨상청miR-29a、miR-29b화miR-29c적수평.등량적외원성인공합성적cel-miR-39가입등체적적뇨상청중용우교정miR-29적수평.동시수집뇨백단백배설솔、혈기항、뇨소담、당화혈홍단백(HbAlc)、혈지등기타생화지표.이안저검사적결과칙작위평고당뇨병소혈관병변적지표.결과 2형당뇨병유、무단백뇨량조지간HbAlc수평급당뇨병병정차이무통계학의의,이2형당뇨병유단백뇨조고산신소구려과솔(eGRF)수평현저저우무단백뇨조(P=0.001),2형당뇨병유단백뇨조뇨상청miR-29a、miR-29b화miR-29c 수평고우무단백뇨조(P=0.029、0.032、0.040).2형당뇨병뇨백단백배설솔여뇨상청miR-29a 급miR-29b수평상관(r=0.284,P=0.039;r=0.275,P=0.046),뇨상청miR-29b수평여뇨소담수평상관(r=0.277,P=0.031),이miR-29수평여상술기타각항림상지표무상관.결론 2형당뇨병환자뇨상청miR-29a급miR-29b수평여뇨백단백수평상관.뇨상청miR-29작위2형당뇨병환자당뇨병신병적생물표지물적잠능유대진일보적탐색화평고.
Objective To investigate the possibility of urinary microRNA-29 (miR-29) as biomarker for diabetic nephropathy in patients with type 2 diabetes.Methods Sixty-one patients with type 2 diabetes were divided into 2 groups:diabetes with normoalbuminuria[n =25,(58.88±11.75)years old] and diabetes with albuminuria[n =36,(62.19±13.11) years old].There were no significant differences in age and gender between groups.The contents of miR-29a,miR-29b and miR-29c in urine supernatant were determined by real-time quantitative PCR,and a synthetic cel-miR-39 was added to the urine as a spike-in control before miRNAs extraction.The laboratory parameters including urinary albumin excretion,serum creatinine,BUN,glycosylated hemoglobin,and blood lipids were collected,while retinopathy serves as non-invasive method to assess vascular fibrosis.Results There was no significant difference in glycosylated hemoglobin levels and duration of diabetes between two groups,while the diabetes with albuminuria group had lower estimated glomerular filtration rate (eGFR)(P =0.001),had higher level of miR-29a,miR-29b and miR-29c in urine (P =0.029,0.032,0.040)compared with diabetes normoalbuminuria group.Urinary albumin excretion rate significantly correlated with urinary miR-29a level (r =0.284,P =0.039) and miR-29b level (r =0.275,P =0.046),urinary miR-29b significantly correlated with BUN (r =0.277,P=0.031)in patients with type 2 diabetes.However,no correlation was found between miR-29a,miR-29b,miR-29c and other clinical parameters.Conclusion Urinary miR-29a and miR-29b correlates with urinary albumin in patients with type 2 diabetes,and it needs further exploration and evaluation for urinary miR-29 to serve as potential biomarker for diabetic nephropathy in type 2 diabetes.